These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38780693)

  • 21. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
    Goetze TO; Reichart A; Bankstahl US; Pauligk C; Loose M; Kraus TW; Elshafei M; Bechstein WO; Trojan J; Behrend M; Homann N; Venerito M; Bohle W; Varvenne M; Bolling C; Behringer DM; Kratz-Albers K; Siegler GM; Hozaeel W; Al-Batran SE
    Ann Surg Oncol; 2024 Jun; 31(6):4073-4083. PubMed ID: 38459418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
    World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
    Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
    Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
    Hann A; Bohle W; Egger J; Zoller WG
    Z Gastroenterol; 2016 Oct; 54(10):1138-1142. PubMed ID: 27723905
    [No Abstract]   [Full Text] [Related]  

  • 31. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
    Erstad DJ; Sojoodi M; Taylor MS; Jordan VC; Farrar CT; Axtell AL; Rotile NJ; Jones C; Graham-O'Regan KA; Ferreira DS; Michelakos T; Kontos F; Chawla A; Li S; Ghoshal S; Chen YI; Arora G; Humblet V; Deshpande V; Qadan M; Bardeesy N; Ferrone CR; Lanuti M; Tanabe KK; Caravan P; Fuchs BC
    Clin Cancer Res; 2020 Sep; 26(18):5007-5018. PubMed ID: 32611647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).
    Snyder RA; Zemla TJ; Shi Q; Segovia D; Ahmad SA; O'Reilly EM; Herman JM; Katz MHG
    Ann Surg Oncol; 2024 Oct; 31(10):7033-7042. PubMed ID: 39008208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH; Shi Q; Ahmad SA; Herman JM; Marsh Rde W; Collisson E; Schwartz L; Frankel W; Martin R; Conway W; Truty M; Kindler H; Lowy AM; Bekaii-Saab T; Philip P; Talamonti M; Cardin D; LoConte N; Shen P; Hoffman JP; Venook AP
    JAMA Surg; 2016 Aug; 151(8):e161137. PubMed ID: 27275632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.